Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>LMR‐101 is a bisphenol derivative of propofol, a short‐acting general anesthetic, which is also used to manage status epilepticus (SE). We evaluated the sedative and anticonvulsant effects of LMR‐101 to discover its potential to manage epilepsy and SE in the clinic.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Comparative studies between LMR‐101 and propofol were performed in mice to elucidate an appropriate dose range for LMR‐101 that produced anticonvulsant effects without significant sedation. Then, the anticonvulsive efficacy for LMR‐101 was evaluated using seizure models induced by pentylenetetrazol and (+)‐bicuculline. The ability of LMR‐101 to inhibit SE was assessed using a rat model of SE induced by pilocarpine. Radioligand binding assay profiles for LMR‐101 were performed to evaluate the potential mechanisms of action underlying its anticonvulsant properties.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>In the mouse study, LMR‐101 exhibited greater anticonvulsant and lesser sedative effect compared with propofol. LMR‐101 completely inhibited pentylenetetrazol‐induced seizures at a dose of 50 mg/kg and exhibited heavy sedation at 300 mg/kg. Propofol anesthetized all mice and only decreased the seizure rate at 25 mg/kg. LMR‐101 also suppressed seizure behaviors evoked by (+)‐bicuculline in mice in a dose‐dependent manner. In the pilocarpine‐induced SE model, LMR‐101 significantly decreased the maximum seizure score and seizure duration in a dose‐dependent manner. The median effective dose for LMR‐101 was 14.30 mg/kg and 121.87 mg/kg to prevent and inhibit sustained SE, respectively. In binding assays, LMR‐101 primarily inhibited <i>tert</i>‐[<sup>35</sup>S] butylbicyclophosphorothionate binding to γ‐aminobutyric acid type A (GABA<sub>A</sub>) receptors (half‐maximal inhibitory concentration = 2.06 μmol·L<sup>–1</sup>), but it did not affect [<sup>3</sup>H] flunitrazepam or [<sup>3</sup>H] muscimol binding. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significance</h3><p>It is anticipated that LMR‐101 might play an essential role in the clinical management of epilepsy and SE. LMR‐101 also might bind to a novel target site on the GABA<sub>A</sub> receptor that is different from existing antiepileptic drugs. Further study of the mechanisms of action of LMR‐101 would be of considerable value in the search for new active drug sites on GABA<sub>A</sub> receptors. </p></section>

Magnolol, A Major Bioactive Constituent of the Bark of Magnolia Officinalis, Exerts Antiepileptic Effects Via the Gaba/Benzodiazepine Receptor Complex in Mice

Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, induces sleep via the benzodiazepine site of GABAA receptor in mice

Magnolol Mitigates Lung Injury in Sepsis Mice by Reducing Inflammatory Response and Oxidative Stress and Regulating HMGB1/TLR4/NF-kappa B Signaling Pathway

Cannabinoid‐like compounds found in non‐cannabis plants exhibit antiseizure activity in genetic mouse models of drug‐resistant epilepsy

Effect of magnolol on cerebral injury and blood brain barrier dysfunction induced by ischemia-reperfusion in vivo and in vitro

The Neuropharmacological Effects of Magnolol and Honokiol: A Review of Signal Pathways and Molecular Mechanisms

(+)-Borneol enantiomer ameliorates epileptic seizure via decreasing the excitability of glutamatergic transmission

Magnolol, a Natural Polyphenol, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice

Insights on the Multifunctional Activities of Magnolol

Computational and Experimental Assessments of Magnolol as a Neuroprotective Agent and Utilization of UiO-66(Zr) as Its Drug Delivery System

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression

Magnolol Ameliorates Behavioral Impairments and Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease

Origanum majorana L. polyphenols: in vivo antiepileptic effect, in silico evaluation of their bioavailability, and interaction with the NMDA receptor

The Antidepressant Effect of Magnolol on Depression-Like Behavior of CORT-Treated Mice

LMR‐101, a novel derivative of propofol, exhibits potent anticonvulsant effects and possibly interacts with a novel target on γ‐aminobutyric acid type A receptors

Anti-angiogenic and anti-inflammatory effect of Magnolol in the oxygen-induced retinopathy model

(+)-Borneol inhibits neuroinflammation and M1 phenotype polarization of microglia in epileptogenesis through the TLR4-NFκB signaling pathway

Magnolol as STAT3 Inhibitor for Treating Multiple Sclerosis by Restricting Th17 Cells

Magnolol Attenuates Sepsis-Induced Gastrointestinal Dysmotility in Rats by Modulating Inflammatory Mediators

Regulating the NMDA/NR2B signaling pathway mediates anticonvulsant, antineuroinflammation, and anti-oxidative stress effects of 1,3,benzothiazole derivative 1M in pentylenetetrazole-induced kindling in mice

Anticonvulsant Activity of trans-Anethole in Mice